Last reviewed 2026-04-23 · How we verify

HPP2003-3

HPP2003-3 is a long-acting GLP-1 receptor agonist designed to improve glycemic control in diabetes by enhancing insulin secretion and reducing glucagon release.

HPP2003-3 is a long-acting GLP-1 receptor agonist designed to improve glycemic control in diabetes by enhancing insulin secretion and reducing glucagon release. Used for Type 2 diabetes mellitus.

At a glance

Mechanism of action

HPP2003-3 activates glucagon-like peptide-1 (GLP-1) receptors on pancreatic beta cells and alpha cells, stimulating glucose-dependent insulin secretion while suppressing glucagon secretion. The extended half-life formulation allows for less frequent dosing compared to shorter-acting GLP-1 agonists, providing sustained glycemic control over extended intervals.

Approved indications

• Type 2 diabetes mellitus

Common side effects

• Nausea
• Vomiting
• Diarrhea
• Hypoglycemia

Key clinical trials

• A Study to Evaluate Efficacy and Safety of HCP1803 Compared to RLD2001-1 in Patients with Essential Hypertension (PHASE3)
• A Study to Evaluate Efficacy and Safety of HCP1803 in Patients With Essential Hypertension (PHASE3)
• A Phase 2 Study to Explore the Dose of HCP1803 in Patients With Essential Hypertension (PHASE2)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

• HPP2003-3 CI brief — competitive landscape report
• HPP2003-3 updates RSS · CI watch RSS
• Hanmi Pharmaceutical Company Limited portfolio CI